Nilotinib
| File:Nilotinib.svg | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C28H22F3N7O |
| Molar mass | 529.516 g/mol |
|
WikiDoc Resources for Nilotinib |
|
Articles |
|---|
|
Most recent articles on Nilotinib |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Nilotinib at Clinical Trials.gov Clinical Trials on Nilotinib at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Nilotinib
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Nilotinib Discussion groups on Nilotinib Directions to Hospitals Treating Nilotinib Risk calculators and risk factors for Nilotinib
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Nilotinib |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Nilotinib, in the form of the hydrochloride monohydrate salt, is a tyrosine kinase inhibitor approved as Tasigna® in the USA and the EU for drug-resistant chronic myelogenous leukemia (CML)[1]. In June 2006, a Phase I clinical trial found nilotinib, also known by its clinical code AMN107, has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec®), another tyrosine kinase inhibitor currently used as a first-line treatment.[2] In that study 92% of patients (already resistant or unresponsive to Gleevec) achieved a normal white blood cell counts after 5 month of treatment. [3]
The drug will carry a black box warning for possible heart complications. [4]
References
- ↑ Novartis 29/10/2007 Press Release.
- ↑ Kantarjian H; et al. (2006). "Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL". N Engl J Med. 354 (24): 2542–51. PMID 16775235.
- ↑ http://cws.huginonline.com/N/134323/PR/200606/1056533_5.html Patients with treatment-resistant leukemia achieve high responses to Tasigna® (nilotinib) in first published clinical trial results - Novartis 14/06/2006 Press Release.
- ↑ http://www.fda.gov/bbs/topics/NEWS/2007/NEW01734.html FDA Approves Tasigna for Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia - FDA 31/10/2007 Press Release
- Pages with script errors
- CS1 maint: Explicit use of et al.
- Pages with broken file links
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Chemotherapeutic agents
- Orphan drugs
- Tyrosine kinase inhibitors